Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Acute STEMI
NCT03004703Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Mar 2017
- Primary completion
- Feb 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in ST-segment elevation myocardial infarction (STEMI), sponsored by Oslo University Hospital. Started Mar 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03004703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004703.